Re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskj?t, J?rgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol. In press

被引：0

作者：

Pradere, Benjamin ^{[1
,2
]}

Basile, Giuseppe ^{[3
]}

Seisen, Thomas ^{[4
,5
]}

机构：

[1] La Croix Du Sud Hosp, Dept Urol UROSUD, Quint Fonseg Rives, France

[2] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria

[3] IRCCS San Raffaele Hosp, Dept Urol, Milan, Italy

[4] Sorbonne Univ, Pitie Salpetriere Hosp, APHP, Dept Urol,GRC 5,Predict Oncourol, Paris, France

[5] Sorbonne Univ, Pitie Salpetriere Hosp, APHP, Dept Urol, 47-83 Blvd Hop, F-75013 Paris, France

来源：

EUROPEAN UROLOGY | 2023年 / 83卷 / 04期

关键词：

D O I：

10.1016/j.eururo.2022.12.036

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E105 / E106

页数：2

共 6 条

[1] Reply to Benjamin Pradere, Giuseppe Basile, and Thomas Seisen's Letter to the Editor re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjot, Jorgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol 2023;41:2,206-11
Lindgren, Maria S.
Jensen, Jorgen B.
EUROPEAN UROLOGY, 2023, 83 (04) : E107 - E108
[2] DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial
Lindgren, Maria S.
Hansen, Erik
Azawi, Nessn
Nielsen, Anna M.
Dyrskjot, Lars
Jensen, Jorgen B.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 206 - +
[3] Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial
Chang, Sam S.
JOURNAL OF UROLOGY, 2023, 209 (06): : 1228 - 1229
[4] DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial (vol 41, pg 206, 2023)
不详
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (08)
[5] Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-62
Signorini, Claudia
Maffezzini, Massimo
EUROPEAN UROLOGY, 2021, 79 (05) : E135 - E136
[6] Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-62
Lindgren, Maria S.
Jensen, Jorgen B.
EUROPEAN UROLOGY, 2021, 79 (05) : E137 - E137

← 1 →